Picture loading failed.

Anti-CEACAM5 therapeutic antibody (Pre-made Labetuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. It selectively binds to carcinoembryonic cell adhesion molecule 5.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-288-1mg 1mg Inquiry
GMP-Bios-ab-288-10mg 10mg Inquiry
GMP-Bios-ab-288-100mg 100mg Inquiry
GMP-Bios-ab-288-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CEACAM5 therapeutic antibody (Pre-made Labetuzumab biosimilar,Whole mAb ADC)
INN Name Labetuzumab
TargetCEACAM5
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesImmunomedics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedColorectal cancer;Ovarian cancer;Breast cancer
Development Techna